Superiority of Denosumab over Bisphosphonates in Preventing and Treating Glucocorticoid-induced Osteoporosis: a Systematic Review and Meta-analysis with GRADE Quality Assessment

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2025 Jan 2

PMID 39744180

Authors

Chiao-Ling Chen

Jian-Ying Wang

Affiliations

Soon will be listed here.

Abstract

Background: The increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative efficacy and safety profiles.

Methods: We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. Our analysis included randomized controlled trials (RCTs) comparing denosumab with bisphosphonates in GIOP management. The outcomes were percent changes in bone mineral density (BMD) at various sites, bone turnovers markers (BTMs) and the incidence of adverse events.

Results: Our study comprised five RCTs with 1,043 participants. The results showed a significant mean difference in BMD percentage change from baseline at LS of 2.87% (95% CI: 1.86 to 3.87, <0.001) and at TH of 1.39% (95% CI: 0.15 to 2.64, =0.03). Additionally, the safety profile of denosumab was found to be comparable to bisphosphonates, with no significant increase in the incidence of adverse events or serious adverse reactions.

Conclusions: Denosumab proved more effective in enhancing BMD than bisphosphonates in GIOP, maintaining a comparable safety profile. However, the study's limitations, including heterogeneity and the need for longer-term research, were noted.

References

Lyu H, Jundi B, Xu C, Tedeschi S, Yoshida K, Zhao S . Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2018; 104(5):1753-1765. PMC: 6447951. DOI: 10.1210/jc.2018-02236. View

Watts N, Roux C, Modlin J, Brown J, Daniels A, Jackson S . Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos Int. 2011; 23(1):327-37. PMC: 3249159. DOI: 10.1007/s00198-011-1755-2. View

Compston J . Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis. Eur J Endocrinol. 2023; 188(3):R46-R55. DOI: 10.1093/ejendo/lvad029. View

Overman R, Yeh J, Deal C . Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2012; 65(2):294-8. DOI: 10.1002/acr.21796. View

Kong S, Kim J, Kim S, Jeong A, Lee S, Ye S . Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis. J Bone Metab. 2022; 29(2):93-101. PMC: 9208900. DOI: 10.11005/jbm.2022.29.2.93. View

Messina O, Vidal L, Wilman M, Bultink I, Raterman H, Lems W . Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res. 2021; 33(4):793-804. DOI: 10.1007/s40520-021-01823-0. View

Nakamura Y, Suzuki T, Kato H . Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. Ther Clin Risk Manag. 2017; 13:1343-1348. PMC: 5640396. DOI: 10.2147/TCRM.S142828. View

Hofbauer L, Zeitz U, Schoppet M, Skalicky M, Schuler C, Stolina M . Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009; 60(5):1427-37. DOI: 10.1002/art.24445. View

Saag K, Pannacciulli N, Geusens P, Adachi J, Messina O, Morales-Torres J . Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol. 2019; 71(7):1174-1184. PMC: 6619388. DOI: 10.1002/art.40874. View

10.

Geusens P, Bevers M, van Rietbergen B, Messina O, Lespessailles E, Oliveri B . Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment. J Bone Miner Res. 2022; 37(6):1136-1146. PMC: 9324223. DOI: 10.1002/jbmr.4551. View

11.

Buckley L, Humphrey M . Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018; 379(26):2547-2556. DOI: 10.1056/NEJMcp1800214. View

12.

Yamaguchi Y, Morita T, Kumanogoh A . The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. Rheumatol Adv Pract. 2020; 4(1):rkaa008. PMC: 7197806. DOI: 10.1093/rap/rkaa008. View

13.

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15(6):993-1000. DOI: 10.1359/jbmr.2000.15.6.993. View

14.

Mok C, Ho L, Leung S, Cheung H, Chen S, Ma K . Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Bone. 2021; 146:115902. DOI: 10.1016/j.bone.2021.115902. View

15.

Mok C, Ho L, Ma K . Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015; 75:222-8. DOI: 10.1016/j.bone.2015.03.002. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Tamechika S, Ohmura S, Maeda S, Naniwa T . Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids. J Bone Miner Metab. 2022; 41(2):203-211. DOI: 10.1007/s00774-022-01393-9. View

18.

Dong B, Zhou Y, Wang J, Li C, Fu Z, Huang Y . Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2023; 55(4):236-244. DOI: 10.1055/a-2015-1747. View

19.

Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T . The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. PLoS One. 2018; 13(3):e0193846. PMC: 5854344. DOI: 10.1371/journal.pone.0193846. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View